Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Molecular Therapy Année : 2024

Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss

Résumé

Hearing loss is a major health concern affecting millions of people worldwide with currently limited treatment options. In clarin-2-deficient Clrn2/ mice, used here as a model of progressive hearing loss, we report synaptic auditory abnormalities in addition to the previously demonstrated defects of hair bundle structure and mechanoelectrical transduction. We sought an in-depth evaluation of viral-mediated gene deliveryas a therapy for these hearing-impaired mice. Supplementationwith either the murine Clrn2 or human CLRN2 genes preservednormal hearing in treated Clrn2/ mice. Conversely,mutated forms of CLRN2, identified in patients with postlingualmoderate to severe hearing loss, failed to prevent hearing loss. The ectopic expression of clarin-2 successfully prevented the loss of stereocilia, maintained normal mechanoelectrical transduction, preserved inner hair cell synaptic function, and ensured near-normal hearing thresholds over time. Maximal hearing preservation was observed when Clrn2 was delivered prior to the loss of transducing stereocilia. Our findings demonstrate that gene therapy is effective for the treatment of post-lingual hearing impairment and age-related deafness associated with CLRN2 patient mutations.
Fichier principal
Vignette du fichier
2024_Mendia_Clarin2_Gene_Therapy.pdf (11.42 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

pasteur-04550389 , version 1 (17-04-2024)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Clara Mendia, Thibault Peineau, Mina Zamani, Chloé Felgerolle, Nawal Yahiaoui, et al.. Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss. Molecular Therapy, 2024, 32 (3), pp.800-817. ⟨10.1016/j.ymthe.2024.01.021⟩. ⟨pasteur-04550389⟩
15 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More